Cegedim Sa · EURONEXT:ALCGM
Cegedim Sa — FY2018 Earnings Presentation
18 slides from Cegedim Sa's earnings presentation, Jan 29, 2019
Slide 1: FY 2018 Revenues Conference Call
me cegedim FY 2018 Revenues Conference Call January 29", 2019
Slide 2: Caution Concerning Forward-Looking Statements
Caution Concerning Forward-Looking Statements 2 This presentation contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are based on expectations and assumptions that we believe to be reasonable when made, but tha
Slide 3: IFRS Rules
IFRS Rules 3 IFRS 5: Owing to the disposal of the Group’s Cegelease and Eurofarmat businesses, announced in 2017 and completed on February 28, 2018, the consolidated 2017 and 2018 financial statements are presented according to IFRS 5, “Non-current assets held for sale and discontinued”. See the ann
Slide 4: Q4 and FY18 Revenue
4 Q4 and FY18 Revenue Revenue Like-for-like growth picked up speed in Q4-18 4
Slide 5: Q4 2018 Revenue Growth
Q4 2018 Revenue Growth 5 5 © cegedim 2019
Slide 6: FY18 Revenue Growth
FY18 Revenue Growth 6 © cegedim 2019
Slide 7: BPO Revenue
eee §=§=BPO Revenue Revenue FY18 Chart legend Nb fe Lr st Qh tb AY Quis © cegedim 2019
Slide 8: Headcount
in telemedecine CS ageclim ee §=Headcount Revenue FY18 +7.0% 5 = (aon a 61% rte (issn), Nea Ss < See 4,525 3,404 Z Y y 4G 4 Investment y y Z Z JUN. 2015 DEC. 2016 Dec. 2017 JUN. 2018 DEC. 2018 © cegedim 2019
Slide 9: Health Insurance, HR & e-services Division
Health Insurance, HR & e-services Division 9 The businesses that made the strongest contributions to growth over 2018 were Cegedim SRH (HR management solutions), Cegedim Health Data (sales statistics for pharmaceutical products), Cegedim e-business (digitalization and data exchange), and third-party
Slide 10: Healthcare Professionals Division
Healthcare Professionals Division 10 The businesses that made the strongest contributions to this growth were software for doctors and allied health professionals in France and Belgium, and the BCB medication database. The strong year-on-year growth in computerization services for doctors in the UK
Slide 11: FY 2018 Cegedim Outlook
11 FY 2018 Cegedim Outlook Finance as of January 29, 2019
Slide 12: Outlook: Cautiously Optimistic for 2018
Outlook: Cautiously Optimistic for 2018 12 • The Group expects for 2018: 12 These projections are publicly disclosed on Jan. 29, 2019. The fact that Cegedim includes these projections in this presentation should not be taken to mean that these projections continue to be our projections as of any sub
Slide 13: Potential Impact of Brexit
Potential Impact of Brexit 13 • Cegedim operates in the UK in local currency, as it does in all the countries where it operates • No major European health program is at work in the UK 13 © cegedim 2019
Slide 14: 2018 Financial Calendar
2018 Financial Calendar 14 17 © cegedim 2019
Slide 15: FY 2018 Revenue Annexes
15 FY 2018 Revenue Annexes as of January 29, 2019 14
Slide 16: Application of IFRS 5
Application of IFRS 5 16 On December 14, 2017, Cegedim announced that it had signed a contract for the definitive sale of its Cegelease and Eurofarmat businesses. The deal was finalized on February 28, 2018. As a result, the consolidated 2017 and 2018 financial statements are presented according to
Slide 17: Follow us
Follow us 17 WEB SITE www.cegedim.com/finance IR APP WEBCAST CEGEDIM IR SOCIAL NETWORK 18 @cegedimgroup © cegedim 2019
Slide 18: Jan Eryk Umiastowski
18 Jan Eryk Umiastowski Chief Investment Officer – Head of Investor Relations janeryk.umiastowski@cegedim.com Tel: 00 33 1 49 09 33 36 - Mob: 00 33 6 73 25 96 34 Design: Group Communications Department